Nutriband met with US FDA to obtain feedback on the Chemistry, Manufacturing, and Controls plans for AVERSA™ FENTANYL (abuse deterrent ...

Nutriband met with US FDA to obtain feedback on the Chemistry, Manufacturing, and Controls plans for AVERSA™ FENTANYL (abuse deterrent ...

Nutriband met with US FDA to obtain feedback on the Chemistry, Manufacturing, and Controls plans for AVERSA FENTANYL (abuse deterrent transdermal system) through commercialization. Nutriband received ...

Nutriband ( ($NTRB) ) has shared an update. Nutriband Inc. announced the successful completion of a meeting with the US FDA regarding its AVERSA™ ...

A batch of fentanyl transdermal patches have been recalled nationwide by Alvogen Inc. on Friday as the company warned on Friday that there is potential that they could be multi-stacked leading to life ...

Nutriband is developing the product in partnership with Kindeva, combining Nutriband’s AVERSA™ abuse-deterrent technology with Kindeva’s FDA-approved fentanyl patch. The company estimates AVERSA™ ...

ORLANDO, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:NTRB)(NASDAQ:NTRBW) has announced that Company founder, Gareth Sheridan has returned as Company CEO. During the period of August 10 until ...

Featured In Channelchek Report Highlighting AVERSA Fentanyl Progress. Nutriband (NASDAQ: NTRB), a pharmaceutical company developing transdermal drug delivery technologies, was featured in a Channelche ...

Nutriband (NASDAQ: NTRB), a pharmaceutical company developing transdermal drug delivery technologies, was featured in a Channelchek report by Noble Capital Markets summarizing its presentation at ...

Nutriband said Mr Sheridan would guide the company through the rest of the year with the target of a new drug filing for the US Food and Drug Administration in 2026 for its fentanyl patch ...

Founder Gareth Sheridan Returns As CEO To Lead Final Development Phase Of AVERSA Fentanyl. Nutriband (NASDAQ: NTRB) today announced that company founder Gareth Sheridan has resumed his role as CEO, ...